Open Label, Multi-center, Phase 2 Study of KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) Previously Treated With First-Line Chemotherapy
Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Non-Small Cell Lung Cancer
Both
Non-Small Cell Lung Cancer
Trial Information
Open Label, Multi-center, Phase 2 Study of KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) Previously Treated With First-Line Chemotherapy
Inclusion Criteria:
- Histologically or cytologically proven NSCLC, Stage IIIB or Stage IV.
- Eligible patients must have received only one prior chemotherapy regime for Stage
IIIB/IV NSCLC.
- Good performance status.
Exclusion Criteria:
- Prior treatment with an epothilone.
- Known central nervous system (CNS) metastases.
- Any chemotherapy, radiation therapy or immunotherapy or any investigational agent
(therapeutic or diagnostic) within 3 weeks prior to first study drug administration.
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Objective response rate of KOS-1584
Outcome Time Frame:
up to one year
Safety Issue:
No
Principal Investigator
Bristol-Myers Squibb
Investigator Role:
Study Director
Investigator Affiliation:
Bristol-Myers Squibb
Authority:
United States: Food and Drug Administration
Study ID:
CA202-002
NCT ID:
NCT00651508
Start Date:
April 2008
Completion Date:
October 2008
Related Keywords:
- Non-Small Cell Lung Cancer
- Patients with Advanced or Metastatic stage IIIB/IV Non-Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|---|
| Consultants In Blood Disorders & Cancer | Louisville, Kentucky 40207 |
